Tandem Diabetes Care Statistics
Tandem Diabetes Care (0M0F) Stock Statistics & Valuation Metrics
Total Valuation
Tandem Diabetes Care has a market cap or net worth of $1.40B. The enterprise value is $1.43B.
- Market Cap
- $1.40B
- Enterprise Value
- $1.43B
Share Statistics
Tandem Diabetes Care has 69,793,846 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 69,793,846
- Owned by Insiders
- 1.00%
- Owned by Institutions
- 76.83%
Financial Efficiency
Tandem Diabetes Care’s return on equity (ROE) is -1.32 and return on invested capital (ROIC) is -11.88%.
- Return on Equity (ROE)
- -1.32
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -11.88%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 405.89K
- Profits Per Employee
- -81.88K
- Employee Count
- 2,500
- Asset Turnover
- 1.15
- Inventory Turnover
- 3.76
Valuation Ratios
The current PE Ratio of Tandem Diabetes Care is -27.93. Tandem Diabetes Care’s PEG ratio is -0.18.
- PE Ratio
- -27.93
- PS Ratio
- 1.30
- PB Ratio
- 10.35
- Price to FCF
- -38.59
- Price to Operating Cash Flow
- -95.70
- PEG Ratio
- -0.18
Income Statement
In the last 12 months, Tandem Diabetes Care had revenue of 1.01B and earned -204.71M in profits. Earnings per share was -3.04.
- Revenue
- 1.01B
- Gross Profit
- 530.85M
- Operating Income
- -78.12M
- Pretax Income
- -200.27M
- Net Income
- -204.71M
- EBITDA
- -174.70M
- Earnings Per Share (EPS)
- -3.04
Cash Flow
In the last 12 months, operating cash flow was -14.61M and capital expenditures -21.69M, giving a free cash flow of -36.30M billion.
- Operating Cash Flow
- -14.61M
- Free Cash Flow
- -36.30M
- Free Cash Flow per Share
- -0.52
Dividends & Yields
Tandem Diabetes Care pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.59%
- Earnings Yield
- -3.52%
Stock Price Statistics
- Beta
- 1.28
- 52-Week Price Change
- 14.56%
- 50-Day Moving Average
- 17.39
- 200-Day Moving Average
- 18.79
- Relative Strength Index (RSI)
- 60.78
- Average Volume (3m)
- 727
Important Dates
Tandem Diabetes Care upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Tandem Diabetes Care as a current ratio of 2.55, with Debt / Equity ratio of 286.44%
- Current Ratio
- 2.55
- Quick Ratio
- 2.02
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- -2.03
- Interest Coverage Ratio
- -9.88
Taxes
In the past 12 months, Tandem Diabetes Care has paid 4.44M in taxes.
- Income Tax
- 4.44M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Tandem Diabetes Care EV to EBITDA ratio is -120.69, with an EV/FCF ratio of -56.88.
- EV to Sales
- 1.92
- EV to EBITDA
- -120.69
- EV to Free Cash Flow
- -56.88
- EV to Operating Cash Flow
- -141.33
Balance Sheet
Tandem Diabetes Care has $443.08M in cash and marketable securities with $736.54M in debt, giving a net cash position of -$293.46M billion.
- Cash & Marketable Securities
- $443.08M
- Total Debt
- $736.54M
- Net Cash
- -$293.46M
- Net Cash Per Share
- -$4.20
- Tangible Book Value Per Share
- $1.94
Margins
Gross margin is 56.65%, with operating margin of -2.35%, and net profit margin of -4.58%.
- Gross Margin
- 56.65%
- Operating Margin
- -2.35%
- Pretax Margin
- -4.05%
- Net Profit Margin
- -4.58%
- EBITDA Margin
- -1.59%
- EBIT Margin
- -3.26%
Analyst Forecast
The average price target for Tandem Diabetes Care is $28.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $28.60
- Price Target Upside
- 42.82% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 13
- Revenue Growth Forecast
- 6.73%
- EPS Growth Forecast
- 76.54%
Scores
- Smart Score
- 6
- AI Score
- ―

